Sanofi: Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable targetNurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones for this program as well as potential future royalties and retains an option to co-develop and co-promote in the United States with the parties splitting U.S. profits and lossesSAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that Sanofi has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases. The undisclosed target is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program."Using our DEL-AI platform, we successfully identified novel binders from which we derived a series of targeted protein degraders and stand-alone target binders for this previously undruggable target," said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. "This high value target is a transcription factor involved in the regulation of proinflammatory cytokines serving as a central regulator of inflammation response in autoimmune diseases where targeted protein degradation could offer an innovative treatment option.""Sanofi's dedication to this program expands our mutual drug discovery pipeline in autoimmune disease and speaks to the productivity of our collaboration," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "In addition, the highly novel nature of this target further validates the power of Nurix's DEL-AI discovery platform to drive the discovery and development of truly innovative drugs. Partnerships are an important part of Nurix's business model, adding non-dilutive capital and expanding our pipeline by retaining product opt-in rights in the United States. To date, Nurix has received $460 million from partners, including $105 million in payments received from the Sanofi collaboration. We look forward to continuing to advance these programs together with Sanofi, with the shared goal of providing new therapeutic options for patients with autoimmune and inflammatory disorders."Under the collaboration agreement, Nurix is deploying its proprietary DEL-AI drug discovery ...Full story available on Benzinga.com